Company profile
MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07615010 | phase2 | recruiting | 2026-05-26 | 2027-06-01 | MiNK Therapeutics | A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure |
| NCT04582201 | phase1 | completed | 2020-09-21 | 2023-04-23 | MiNK Therapeutics | A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS |
| NCT05108623 | phase1 | completed | 2022-01-28 | 2024-01-02 | MiNK Therapeutics | A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors |
| NCT04754100 | phase1 | completed | 2021-03-29 | 2023-01-13 | MiNK Therapeutics | agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma |
FDA applications (0)
No records yet.